Vitamin D receptor (VDR) localization in human promyelocytic leukemia cells

Leukemia and Lymphoma

Volumn 47, Issue 4, 2006, Pages 727-732

  Wu Wong, J Ruth ^a   Nakane, Masaki ^a   Ma, Junli ^a   Dixon, Doug ^a   Gagne, Gerard ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

19 nor 1 ,25 (OH)2D2; Confocal; HL 60; Paricalcitol; Vitamin D analogs; Vitamin D receptor

Indexed keywords

1,25 DIHYDROXYERGOCALCIFEROL; CALCITRIOL; MESSENGER RNA; VITAMIN D RECEPTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOPLASM; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; TIME;

CELL NUCLEUS; CYTOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; ERGOCALCIFEROLS; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICROSCOPY, CONFOCAL; PROTEIN BINDING; PROTEIN TRANSPORT; RECEPTORS, CALCITRIOL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEROID HYDROXYLASES;

EID: 33646771392     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190500398898     Document Type: Article

References (26)

1. Brown, A and Dusso, A and Slatopolsky, E. (2002) Vitamin D analogues for secondary hyperparathyroidism Nephrology Dialysis Transplants, 17, pp. 10-19.
2. Wu-Wong, J and Tian, J and Goltzman, D. (2004) Vitamin D analogs as therapeutic agents: A clinical study update Current Opinions in Investigative Drugs, 5, pp. 320-326.
3. Carlberg, C and Quack, M and Herdick, M and Bury, Y and Polly, P and Toell, A. (2001) Central role of VDR conformations for understanding selective actions of vitamin D(3) analogues Steroids, 66, pp. 213-221.
4. Slatopolsky, E and Brown, A and Dusso, A. (1999) Pathogenesis of secondary hyperparathyroidism Kidney International Supplement, 73, pp. S14-S19.
5. Ritz, E and Stefanski, A and Rambausek, M. (1995) The role of the parathyroid glands in the uremic syndrome American Journal of Kidney Disease, 26, pp. 808-813.
6. Martin, K and Gonzalez, E. (2004) Vitamin D analogs: Actions and role in the treatment of secondary hyperparathyroidism Seminars in Nephrology, 24, pp. 456-459.
7. Hanchette, C and Schwartz, G. (1992) Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation Cancer, 70, pp. 2861-2869.
8. Banerjee, P and Chatterjee, M. (2003) Antiproliferative role of vitamin D and its analogs - a brief overview Molecular Cell Biochemistry, 253, pp. 247-254.
9. Albertson, D and Ylstra, B and Segraves, R and Collins, C and Dairkee, S and Kowbel, D et al. (2000) Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene Natural Genetics, 25, pp. 144-146.
10. Bortman, P and Folgueira, M and Katayama, M and Snitcovsky, I and Brentani, M. (2002) Antiproliferative effects of 1,25-dihydroxyvitamin D3 on breast cells: A mini review Brazilian Journal of Medical Biology Research, 35, pp. 1-9.
11. Shabahang, M and Buras, R and Davoodi, F and Schumaker, L and Nauta, R and Evans, S. (1993) 1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition Cancer Research, 53, pp. 3712-3718.
12. Mimori, K and Tanaka, Y and Yoshinaga, K and Masuda, T and Yamashita, K and Okamoto, M et al. (2004) Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer Annals of Oncology, 15, pp. 236-241.
13. James, S and Williams, M and Newland, A and Colston, K. (1999) Leukemia cell differentiation: Cellular and molecular interactions of retinoids and vitamin D General Pharmacology, 32, pp. 143-154.
14. Brumbaugh, P and Haussler, M. (1974) 1 Alpha,25-dihydroxycholecalciferol receptors in intestine. II. Temperature-dependent transfer of the hormone to chromatin via a specific cytosol receptor Journal of Biological Chemistry, 249, pp. 1258-1262.
15. Balmain, N and Hauchecorne, M and Pike, J and Cuisinier-Gleizes, P and Mathieu, H. (1993) Distribution and subcellular immunolocalization of 1,25-dihydroxyvitamin D3 receptors in rat epiphyseal cartilage Cellular & Molecular Biology (Noisy-le-grand), 39, pp. 339-350.
16. Barsony, J and Renyi, I and McKoy, W. (1997) Subcellular distribution of normal and mutant vitamin D receptors in living cells Studies with a novel fluorescent ligand. Journal of Biological Chemistry, 272, pp. 5774-5782.
17. Babidge, W and Millard, S and Roediger, W. (1998) Sulfides impair short chain fatty acid beta-oxidation at acyl-CoA dehydrogenase level in colonocytes: Implications for ulcerative colitis Molecular Cell Biochemistry, 181, pp. 117-124.
18. Htun, H and Barsony, J and Renyi, I and Gould, D and Hager, G. (1996) Visualization of glucocorticoid receptor translocation and intranuclear organization in living cells with a green fluorescent protein chimera Proceedings of the National Academy of Sciences (USA), 93, pp. 4845-4850.
19. Huhtakangas, J and Olivera, C and Bishop, J and Zanello, L and Norman, A. (2004) The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1 alpha,25(OH)2-vitamin D3 in vivo and in vitro Molecular Endocrinology, 18, pp. 2660-2671. Epub 2004 Jul 2622
20. Solvsten, H and Svendsen, M and Fogh, K and Kragballe, K. (1997) Upregulation of vitamin D receptor levels by 1,25(OH)2 vitamin D3 in cultured human keratinocytes Archives of Dermatology Research, 289, pp. 367-372.
21. Hulla, W and Kallay, E and Krugluger, W and Peterlik, M and Cross, H. (1995) Growth control of human colon-adenocarcinoma-derived Caco-2 cells by vitamin-D compounds and extracellular calcium in vitro: Relation to c-myc-oncogene and vitamin-D-receptor expression International Journal of Cancer, 62, pp. 711-716.
22. Taoka, T and Collins, E and Irino, S and Norman, A. (1993) 1,25(OH)2-vitamin D3 mediated changes in mRNA for c-myc and 1,25(OH)2D3 receptor in HL-60 cells and related subclones Molecular Cell Endocrinology, 95, pp. 51-57.
23. Schwartz, G and Whitlatch, L and Chen, T and Lokeshwar, B and Holick, M. (1998) Human prostate cells synthesize 1,25-dihydroxyvitamin D3 from 25-hydroxyvitamin D3 Cancer Epidemiology Biomarkers Previews, 7, pp. 391-395.
24. Barreto, A and Schwartz, G and Woodruff, R and Cramer, S. (2000) 25-Hydroxyvitamin D3, the prohormone of 1,25-dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells Cancer Epidemiology Biomarkers Previews, 9, pp. 265-270.
25. Martin, K and Gonzalez, E and Gellens, M and Hamm, L and Abboud, H and Lindberg, J. (1998) Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2 American Journal of Kidney Disease, 32, pp. S61-S66.
26. Kumagai, T and O'Kelly, J and Said, J and Koeffler, H. (2003) Vitamin D2 analog 19-nor-1,25-dihydroxyvitamin D2: Antitumor activity against leukemia, myeloma, and colon cancer cells Journal of the National Cancer Institute, 95, pp. 896-905.